Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.

被引：2
|
作者：
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Kratochwil, Clemens
Baum, Richard P.
Schmidt, Matthias
Pfestroff, Andreas
Prasad, Vikas
Heinzel, Aelxander
Ruf, Juri
Eveslage, Maria
Boegemann, Martin
Fendler, Wolfgang
Krause, Bernd J.
机构：
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
[4] Zentralklin Bad Berka, Bad Berka, Germany
[5] Univ Cologne, Dept Nucl Med, Cologne, Germany
[6] Univ Marburg, Dept Nucl Med, Marburg, Germany
[7] Charite, Dept Nucl Med, Med Ctr, Berlin, Germany
[8] Univ Aachen, Dept Nucl Med, Aachen, Germany
[9] Univ Freiburg, Dept Nucl Med, Freiburg, Germany
[10] Univ Hosp Muenster, IBKF, Munster, Germany
[11] Univ Munster, Med Ctr, Munster, Germany
[12] Univ Munich LMU, Dept Nucl Med, Munich, Germany
[13] Univ Rostock, Dept Nucl Med, Rostock, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [32] Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
    Filss, Christian
    Heinzel, Alexander
    Mueller, Berthold
    Vogg, Andreas T. J.
    Langen, Karl-Josef
    Mottaghy, Felix M.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (01): : 19 - 25
  • [33] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670
  • [34] Patient-specific tumor dosimetry in mCRPC patients treated with 177Lu-PSMA-617
    Meyer, Catherine
    Mirando, David
    Adams, Tim
    Czernin, Johannes
    Calais, Jeremie
    Dahlbom, Magnus
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [35] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [36] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
  • [37] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Khreish, Fadi
    Kochems, Niklas
    Rosar, Florian
    Sabet, Amir
    Ries, Martin
    Maus, Stephan
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
  • [38] 177Lu-PSMA-617: Brazilian Experience
    Villas Boas, Cristian Wieczorek
    Silva, Jefferson de Jesus
    Benedetto, Raquel
    Mengatti, Jair
    De Araujo, Elaine Bortoleti
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [39] 177Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment
    Sahin, Ertan
    Elboga, Umut
    Cimen, Ufuk
    Okuyan, Merve
    Cayirli, Yusuf Burak
    CURRENT RADIOPHARMACEUTICALS, 2024, 17 (04) : 356 - 363
  • [40] Feasibility of 177Lu-PSMA-617 radioligand therapy in a patient with recurrent high-grade glioma
    Holzgreve, A.
    Delker, A.
    Wenter, V.
    Zacherl, M. J.
    Thon, N.
    Harter, P.
    Brendel, M.
    Unterrainer, L. M.
    Niyazi, M.
    Bartenstein, P.
    von Baumgarten, L.
    Albert, N. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S217 - S217
12345